One stock yields 6% today. Another has grown its dividend by 460% over the past decade. Both are blue chip bargains to buy right now.

Targeted therapy revolutionized cancer treatment, with gene fusions leading the way when the FDA approved imatinib in 2001 to ...

MODERNA reported a surprise third-quarter profit on Thursday (Nov 7), driven by cost cutting and higher-than-expected sales ...